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Background
The ARTEMIS trial (TMC114-C211) evaluated LPV/r vs.
DRV/r 800/100 mg OD in treatment-naïve patients, in
combination with TDF/FTC. The TITAN trial (TMC114-
C214) evaluated LPV/r vs. darunavir/ritonavir 600/100
mg BID in LPV-naïve, treatment-experienced patients with
HIV-1 RNA >1000 copies/mL, in combination with opti-
mised NRTI/NNRTI combinations.
Methods
Lipid parameters included total cholesterol, LDL (calcu-
lated, for samples with triglycerides below 4.52 mmol/L),
HDL, triglycerides, apolipoprotein A1, Apo B, glucose and
insulin. Analysis of covariance was used to correlate
changes in each lipid parameter with baseline lipid levels,
age, gender, and race, baseline CD4 count, HIV-RNA,
treatment arm (LPV/r vs. DRV/r), and use of NNRTI
(TITAN trial only) and lipid-lowering drugs (fibrates/stat-
ins). Numbers in brackets show the size of effects of fac-
tors on lipid elevations at week 48 – these effects were all
statistically significant (p < 0.01).
Summary of results
For both trials, baseline CD4 <200 cells/uL or HIV-RNA
>100,000 copies/mL did not correlate with changes in any
lipid parameter.
In ARTEMIS, older patients showed greater rises in total
cholesterol, LDL, triglycerides and Apo B. Men showed
greater rises in triglycerides than women (+31). LPV/r led
to significantly greater rises in total cholesterol (+11 mg/
dL), HDL (+3) and triglycerides (+55). Use of lipid-lower-
ing drugs was infrequent in ARTEMIS (8% in DRV/r arm,
11% in LPV/r arm).
In TITAN, use of NNRTIs led to significantly greater rises
in total cholesterol (+19 mg/dL). LPV/r led to significantly
greater rises in total cholesterol (+9 mg/dL), HDL (+3)
and triglycerides (+47). Men showed greater rises in trig-
lycerides than women (+50). In TITAN, 23% of patients
on DRV/r and 24% on LPV/r used lipid-lowering drugs. In
both trials, adjustment for use of lipid-lowering drugs had
little effect on the estimates of change in any lipid param-
eter for the overall treatment groups. TCHOL/HDL ratios
did not differ significantly between LPV/r and DRV/r in
either trial.
Conclusion
Rises in lipid parameters during the ARTEMIS and TITAN
trials were influenced by several factors, including older
age and use of NNRTIs. Use of DRV/r led to significantly
smaller rises in total cholesterol, HDL and triglycerides
than LPV/r in both trials. Some of the effects on lipids,
while statistically significant, are very small and unlikely
to affect 10-year cardiovascular risks.
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